12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Macitentan: Phase III data

The double-blind, international Phase III SERAPHIN trial in 742 patients with symptomatic PAH showed that once-daily 3 and 10 mg oral macitentan each met the primary endpoint of reducing a composite of time to first morbidity or mortality event vs. placebo. Specifically, low- and high-dose macitentan reduced the risk of a morbidity or mortality event, defined as death, atrial septostomy, initiation of IV or subcutaneous prostanoids, lung transplantation or other worsening of PAH, by 30% and 45%, respectively, compared to placebo (p=0.0108 and p<0.0001). Other worsening of PAH was...

Read the full 424 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >